DOI: 10.1007/s00259-016-3563-6Pages: 689-694

68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients

1. University of Pretoria and Steve Biko Academic Hospital, Department of Nuclear Medicine

2. AZ Groeninge, Department of Nuclear Medicine

3. University Ghent, Department of Radiology and Nuclear Medicine

Correspondence to:
Mike Sathekge
Email: mike.sathekge@up.ac.za

Close

Abstract

Background

To report on imaging findings using 68Ga-PSMA-HBED-CC PET in a series of 19 breast carcinoma patients.

Methods

68Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status.

Results

Out of 81 tumor lesions identified, 84% were identified on 68Ga-PSMA-HBED-CC PET. 68Ga-PSMA-HBED-CC SUVmean values of distant metastases proved significantly higher (mean, 6.86, SD, 5.68) when compared to those of primary or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011). SUVmean values of progesterone receptor-positive lesions proved not significantly different from progesterone receptor-negative lesions. SUV values derived from FDG PET/CT, available in seven patients, and 68Ga-PSMA-HBED-CC PET/CT imaging proved weakly correlated (r = 0.407, p = 0.015).

Conclusions

68Ga-PSMA-HBED-CC PET/CT imaging in breast carcinoma confirms the reported considerable variation of PSMA expression on human solid tumors using immunohistochemistry.

This article is freely available, click here to access the full text/PDF

  • Accepted: Oct 21, 2016
  • Online: Nov 8, 2016

Article Tools

eanm
EJNMMI Ad